BridgeBio's second quarter is the quarter the pipeline became three calendar-dated launches. On May 27 the FDA accepted the BBP-418 NDA with Priority Review, slotting a November 27, 2026 PDUFA date for limb-girdle muscular dystrophy 2I/R9. On August 12 the FDA granted Priority Review to encaleret for autosomal dominant hypocalcemia type 1, locking in a May 8, 2027 PDUFA. The oral infigratinib NDA in achondroplasia was submitted in the quarter, with U.S. launch guided to mid-2027. All three pipeline drugs are now on a clock; Attruby, the company's first product, accelerated +23% quarter over quarter to $222.4M of U.S. net product revenue as the treatment-naive share climbed, real-world evidence versus tafamidis strengthened, and a kidney-protection thesis (post-hoc analyses published in *Circulation: Heart Failure*) added a label-distinct angle. Total revenue reached $243.7M (+120% year over year), operating loss narrowed 20% to $107.1M, and the quarter closed 14 days before a $933.9M preferred-equity financing with Sixth Street and a KKR affiliate that reset the balance sheet for the launch arc. The question the quarter answers is whether BridgeBio can run three near-simultaneous rare-disease launches off a single commercial engine while Attruby's growth curve keeps compounding - and the report's own monitoring items below are the dates that settle it.